

# Index

## A

Aberdeen Prospective Osteoporosis Screening Study (APOSS), 122–123, 279

Acid–base balance

acute acidosis

bone carbonate, 340

calcium release, 337–339

hydrogen ion buffering, 338–339

sodium and potassium, 339–340

chronic acidosis

acidosis-induced alterations, 341–344

bone ion composition, 347–349

calcium release, 340–343

fibroblast growth factor 23, 346–348

hydrogen ion buffering, 350–351

intracellular signaling, 345–347

Pco<sub>2</sub> vs. [HCO<sub>3</sub><sup>-</sup>], 349–350

dietary acid-induced bone resorption, 351–352

metabolic acidosis, 336–337, 351

Adipocytes, 566

Adipose tissue, 322–324

Adrenal glucocorticoids, 46

Adults

bone maintenance, 554

human immunodeficiency virus

cross-sectional studies, 646–647

fractures, 647–648

longitudinal studies, 647

low BMD risk factors, 649

mineral composition of, 380

women protein intake, 308–310

Advanced resistive exercise device (ARED), 691

Aged care, 241

Age-related bone loss, 15

Age-related fractures, 66–67

Alcohol consumption

bone mineral density, 497–499

effects on skeletal health, 496–497

fracture risk, 499–501

nutrition and alveolar bone loss, 139

Alendronate (ALN), 683–684

Alveolar bone loss (ABL)

alcohol, 139

obesity and metabolic syndrome, 136

oral bone loss, 136–138

vitamin D, 139

whole grains and dietary fiber, 136

Amenorrhea, 603

Angiogenesis, 44

Anorexia nervosa (AN)

bone density effect, 602–603

protein malnutrition, 306–307

weight recovery effects, 608

Anti-estrogenic smoking effect, 491

Anti-osteoporosis therapies, 386–388

Antioxidants, nutraceuticals, 589–590

Anti-resorptive therapy, 388

Antiretroviral therapy, HIV, 646

Areal bone mineral density (aBMD),

22, 260–261

Ascorbic acid, 590

Avon Longitudinal Study of Parents and Children

(ALSPAC), 173, 184

## B

Bariatric surgery, 573–574

Basic multicellular unit (BMU), 40

Bicarbonates, 587

Bisphosphonates (BP), 530

denosumab, 683–684

space flight, 692

Blackcohosh. *See* Cimicifuga racemosa(CR)

BMC. *See* Bone mineral content (BMC)

BMD. *See* Bone mineral density (BMD)

Body composition

adipocytes, 566

calcium and vitamin D intake and

effects, 567

genetic markers, 568

lean soft tissue vs. fat tissue mass, 566–567

osteoblasts, 565

- Body mass index (BMI), 184, 267
- Body weight
- body size, 565
  - low body weight
    - bone mineral density, 564
    - bone turnover, 564
    - fracture risk, 564–565
  - obesity
    - body mass index, 562
    - and bone, 562–564
- Bone accrual, 175
- Bone acquisition, 263, 303–305
- Bone biomechanics
- age-related fractures, 66–67
  - skeletal fragility, 75
  - undernutrition and overnutrition, 74–75
  - vitamin D deficiency, 74
  - whole bone strength
    - bone geometry, 69–70
    - collagen characteristics, 73
    - determinants, 67
    - hierarchical nature of factors, 68
    - material vs. structural properties, 68–69
    - matrix mineralization, 72–73
    - microdamage, 73
    - non-collagenous proteins, 73
    - trabecular microarchitecture, 70–72
- Bone calcium. *See also* Calcium
- mobilization, 425, 427
  - retention, 374–375
- Bone carbonate, 340
- Bone densitometry
- biomechanical studies, 85
  - fracture trials, 84–85
- Bone density
- caffeine consumption, 148
  - dietary patterns, 148
  - omega-3 fatty acids, 147
- Boneglaprotein. *See* Osteocalcin (OC)
- Bone health
- adaptation, 7
  - course of human evolution, 7–9
  - culture and adaptation, 6
  - environments, 10
  - evolutionary mechanisms, 4–6
  - exercise programs, 530–533
  - food production
    - cultural effects, 11–12
    - dietary calcium intake, 12–14
  - indices, 123–126
  - physical activity
    - bone mineral density, 507–508
    - childhood and adolescence, 508–512
    - in older men, 520–525
    - in premenopausal women, 512–520
  - physically active lifestyles
    - historic times, 14–15
    - prehistoric times, 14
  - reproductive behavior, 15–17
- Bone ion composition, 347–349
- Bone loss, 232, 417
- Bone mass, 506
- cystic fibrosis, 618
  - determinant, 566–567
  - fruits and vegetables, 146–147
  - genetic markers, 568
  - ipriflavone vs. placebo, 587
  - overweight vs. obese, children, 563
  - protein, 147
  - risk factors, 564
  - voluntary vs. involuntary weight reduction, 569–570
- Bone matrix properties
- collagen characteristics, 73
  - matrix mineralization, 72–73
  - microdamage, 73
  - non-collagenous proteins, 73
- Bone metabolism
- calcium
    - lactation, 162, 165–166
    - pregnancy, 162–164
    - weaning, 162, 167
  - energy deficit, 307–308
  - protein intake effect, 302–303
  - quantitative clinical nutrition (*see* Quantitative clinical nutrition)
  - space flight, 689–690
- Bone microarchitecture
- racial differences, 262–263
  - trabecular, 70–72
- Bone mineral content (BMC), 22
- bone mineral density, 295–296
  - eating disorders, 603
  - fetal and neonatal bone health
    - preterm infants, 191–194
    - term infants, 190–191
  - gene–diet interactions, 22
  - preterm infants, 191–194
  - size-adjusted, 169–170
  - term infants, 190–191
  - vegetarianism, 295–296
- Bone mineral density (BMD), 69
- alcohol consumption, 497–499
  - bone densitometry
    - biomechanical studies, 85
    - fracture trials, 84–85
  - bone mineral content, 295–296
  - calcium, 220, 292–293
  - celiac disease, 635
  - chronic low-grade systemic inflammation, 663
  - clinical research studies, 95
  - cystic fibrosis, 619
  - vs. dietary intake, 122–123
  - dual X-ray absorptiometry, 82–83
    - diagnosis, 91, 92, 94
    - monitoring, 94
    - results, 91–93
    - scan acquisition and analysis, 90
    - site selection, 90
  - epidemiology and basic science, 95
  - flavonoids, 294
  - fracture risk, 88, 250, 297–298
  - low body weight, 564

- lumbar spine and femoral neck, 296
- monitoring of therapy, 89–90
- osteoporosis diagnosis, 86–87
- patient selection, 88–89
- peripheral devices, 84
- phytates/oxalates, 294
- postmenopausal lacto-ovo vegetarians, 295
- preclinical research studies, 95–96
- protein and acid/alkali balance, 293
- quantitative computed tomography, 83–84
- skeletal regions, 688
- smoking
  - bone loss in women and men, 492–493
  - in mid-and late life, 492–494
  - peak bone mass, attainment of, 491
  - skeletal change over lifespan, 491
- vitamin B<sub>12</sub>, 294
- vitamin D, 293
- weight reduction, 568
- Bone mineralization, 427
- Bone physiology
  - angiogenesis, 44
  - bone remodeling cycle
    - activation, 40–41
    - formation, 42–43
    - resorption, 41–42
    - reversal, 41
    - schematic, 39
  - calcium, 49–50
  - epidermal growth factor, 44
  - growth-regulating hormones, 46–47
  - local regulatory factors, 48–49
  - modeling and remodeling, 38–39
  - osteoblasts and osteocytes, 43–44
  - osteoclast lineage, 42–43
  - phosphorus, 49–50
  - sex hormones, 47–48
  - skeletal development, 38
  - systemic hormones, 45–46
  - T-cells, 44
- Bone resorption, 373–374
- Bone turnover, 564
- Boron
  - nutraceuticals, 588
  - preterm infants, 400–401
- Bulimia nervosa (BN), 600
- B vitamins, 588–589
  
- C**
- Calcaneal ultrasound (CUS), 610
- Calcium
  - absorption, 636, 639
  - African Americans
    - intake, 250
    - observational studies, 252
    - postmenopausal black women, 253
    - regulating hormones, 251–252
    - Women's Health Initiative, 253–254
  - balance, 365, 366
  - BMD, 220, 292–293
  - body composition, 567
  - clearance rates, 367
  - clinical recommendations, 226
  - cystic fibrosis
    - absorption, 621
    - accretion and turnover, 622
    - dermal losses, 622
    - direct assessment tool, 620
    - endogenous fecal losses, 621–622
    - urinary calcium excretion, 621
  - deficiency, 233–234
  - dietary intake, 12–14
  - fracture rates, 222–224
  - gene interactions, 26, 29
  - human immunodeficiency virus, 652
  - intake
    - assessment, 106–107
    - food sources, 112
    - recommendations, 224
    - supplements, 113
    - thresholds, 201–202
  - lactose intolerance, 550
  - maximal retention, 219–220
  - metabolism and bone turnover, 372
  - model for, 368, 369
  - osteoporosis, 682
  - parameters
    - absorption, 370–371
    - bone turnover, 372–374
    - <sup>41</sup>Ca usage, 374–375
    - endogenous fecal excretion, 371–372
    - urinary excretion, 371
  - pharmacotherapy, 224
  - phosphate economy, 302–303
  - physiology, 218–219
  - premenopausal women, 551
  - racial differences, 264–265
  - regulation, 49–50
  - safety, 225–226
  - supplementation, 238
  - tracer experiments, 367
  - VDR gene polymorphisms, 25–28
  - voluntary weight reduction, 571
- Candidate gene association studies, 22–23
- Carboxylated form of osteocalcin (cOC), 473, 474
- Carotenoids, 589
- Celiac disease
  - bone loss causes, 636–637
  - clinical presentation, 634
  - complications, 635–636
  - diagnostic algorithm, 637
  - effect, 636
  - intestinal biopsy, 638
  - pathogenic mechanism, 635
  - prevalence and genetics, 634
  - serologic tests, 638
  - treatment, 639–640

- CF transmembrane conductance regulator (CFTR), 618
- Children and adolescents
- bone health
    - exercise, 509–511
    - nonathletic studies, 510
    - physical activity recommendations, 511–512
    - studies of athletes, 509
  - human immunodeficiency virus
    - cross-sectional studies, 648
    - fractures, 649
    - longitudinal studies, 648–649
    - low BMD risk factors, 649
- Chronic acidosis
- acidosis-induced alterations, 341–344
  - bone ion composition, 347–349
  - calcium release, 340–343
  - fibroblast growth factor 23, 346–348
  - hydrogen ion buffering, 350–351
  - intracellular signaling, 345–347
  - Pco<sub>2</sub> vs. [HCO<sub>3</sub><sup>-</sup>], 349–350
- Chronic low-grade systemic inflammation
- effects
    - BMD and osteoporosis, 663
    - fracture risk, 663–664
    - sarcopenia and falls risk, 664–665
  - immunosenscence, 660
  - inflammaging, 661–662
  - origins, 661–662
  - osteoimmunology, 660
  - osteoporosis, nutritional approaches
    - dietary and supplemental calcium, 665–666
    - dietary protein, 670–671
    - magnesium, 672–673
    - milk and dairy foods, 666–667
    - omega-3 fatty acids, 673
    - soy protein and milk peptides, 671
    - vitamin D (*see* Vitamin D)
    - vitamin K, 671–672
  - pro-inflammatory and anti-inflammatory cytokines, 660
- Cimicifuga racemosa (CR), 587
- Circulatory lipids, 324–325
- cOC. *See* Carboxylated form of osteocalcin (cOC)
- Compartmental models, for calcium kinetics, 369–370
- Copper deficiency
- cystic fibrosis, 625–626
  - preterm infants
    - animal studies, 397
    - human studies, 397–398
    - Menkes' kinky hair syndrome, 396
    - necrotizing enterocolitis, 397
    - radiological features, 397
- Cortical bone mineral density, 15
- Corticosteroid treatment, 529
- Cystic fibrosis (CF)
- body weight growth and maintenance, 619–620
  - bone mass, 618
  - bone mineral density, 619
  - calcium
    - absorption, 621
    - accretion and turnover, 622
    - dermal losses, 622
    - direct assessment tool, 620
    - endogenous fecal losses, 621–622
    - urinary calcium excretion, 621
  - CFTR gene mutation, 618
  - copper deficiency, 625–626
  - magnesium, 626
  - metabolic bone disease, 618–619
  - nutrition, genetics, and disease severity, 626–627
  - osteoporosis and osteopenia, 619
  - phosphorus, 626
  - vitamin D
    - absorption, 623
    - and bone, 624
    - health outcomes, 624
    - 25-hydroxyvitamin D, 622
    - metabolism, 622
  - vitamin K, 624–625
  - zinc deficiency, 625
- Cytokine osteoprotegerin (OPG), 164
- Cytokines, 48
- D**
- Dehydroepiandrosterone (DHEA), 586
- Denosumab, 683–684
- Dietary acidity, 283–284
- Dietary Guidelines Advisory Committee (DGAC), 152
- Dietary intake assessment
- food frequency questionnaire, 106
  - 24-hour recall, 104–105
- Dietary pattern analysis
- bone health indices, 123–126
  - dark-green vegetables, 130
  - data collection, 119
  - deep-yellow vegetables, 130
  - dietary assessment, 119
  - dietary intake vs. bone mineral density, 122–123
  - falls-related fracture risk, 130
  - food groupings and energy adjustment, 120–121
  - fracture incidence, 123, 127–129
  - methods, 118
  - nuts and meat, 123
  - partial least squares, 118
  - postmenopausal women, 119
  - processed meats, 130
  - reduced rank regression, 118
  - statistical analysis and interpretation, 121–122
- 1,25-Dihydroxyvitamin D [1,25(OH)<sub>2</sub>D], 251
- Dual-energy X-ray absorptiometry (DXA), 183–184, 574, 608–609
- Dual-isotope procedure, 368
- Dual X-ray absorptiometry (DXA), 82–83
- diagnosis, 91, 92, 94
  - monitoring, 94
  - results, 91–93

scan acquisition and analysis, 90  
 site selection, 90

**E**

## Eating disorders

anorexia nervosa, 600, 602–603, 608  
 bone mineral content, 603  
 bulimia nervosa, 600  
 calcium metabolism, 607–608  
 CUS, 610  
 DSM-IV-TR vs. DSM-V criteria, 600–601  
 DXA, 608–609  
 EDNOS, 600  
 GH resistance, 606–607  
 hypogonadism, 603–606  
 IGF-I, 606–607  
 peptide YY, 607  
 QCT, 609  
 treatment, 610–612

Eating disorders not otherwise specified (EDNOS), 600

Eicosapentaenoic acid (EPA), 694–695

## Elderly

dietary approach, 240–241  
 fracture risk  
   calcium deficiency, 233–234  
   calcium supplementation, 238  
   food fortification, 238–239  
   protein deficiency, 232–233  
   vitamin D deficiency, 234–235  
   vitamin D supplementation, 237–238  
 fragility fractures, 232  
 oral nutritional supplements  
   aged-care, 236  
   falls and fractures, 236–237  
 protein intake, 308–310

Energy, 552–553

Energy deficit (ED), 307–308

Estrogen receptor alpha gene (ESR1), 23

Estrogen response element-binding protein (ERE-BP), 464

## Estrogens, 682

bone mass, 58  
 discontinuation of treatment, 60  
 dose, 61  
 effects, 61  
 hypothalamic-pituitary-ovarian axis, 59  
 interactions, 60  
 intervention, 59–60  
 RANK-ligand pathway, 58  
 route of administration, 60

## Exercise

bisphosphonates, 530  
 corticosteroid treatment, 529  
 hormone replacement therapy, 530  
 oral contraceptive use, 529  
 osteoporotic fracture, 525–529  
 physical activity patterns, 507  
 programs for bone health, 530–533

risks in osteoporosis, 534  
 space flight, 690–692

**F**

## Falls

inflammation and sarcopenia, 664–665  
 oral nutrition supplements, 236–237  
 vitamin D and muscle performance, 221–222

## Fat

adipocytes, 320  
 lipids  
   adipose tissue, 322–324  
   BMD, 327  
   bone biomarkers, 329  
   circulatory, 324–325  
   fish, 328  
   low-carbohydrate–high-fat diet, 327  
   omega-3 fatty acid, 327  
   osteoporosis, 329  
   peroxisome proliferator-activated receptor-  
     gamma, 325–326  
   postmenopausal women, 328  
 osteocalcin, 319  
 systemic effects  
   body weight, 321  
   energy storage, 320  
   high-energy industrialized foods, 320  
   intestine microbiota, 321  
   n-3 and n-6 polyunsaturated fatty acids, 322

## Fetal and neonatal bone health

bone mineral content  
   preterm infants, 191–194  
   term infants, 190–191  
 developmental programming  
   body mass index, 184  
   breastfeeding, 185  
   folate, 184  
   intrauterine growth restriction, 186  
   maternal physical exercise, 186  
   maternal vitamin D insufficiency, 185  
   total bone less head, 184  
   vitamin D receptor, 185  
 nutritional deficiency/excess, 189–190  
 skeletal development  
   calcium, 186–187  
   maternal nutrition, 187  
   minerals, 186  
   premature infants, 188  
   term-born infants, 188–189

## Fetal growth, 171

Fibroblast growth factor 23 (FGF23), 346–348

Fish oil, 413

Flavonoids, 294, 589

Fluoride, 50, 145–146, 403

Folate, 30, 589

Food fortification, 238–239

Food frequency questionnaire (FFQ), 106, 474, 477

## Food groups

- dietary quality, 279
- energy adjustment, 120–121
- fruit and vegetables
  - acid–base imbalance, 282–283
  - population-based and intervention studies, 284
  - potential renal acid load, 283–284
- hot and cold beverages, 284–285
- meat/animal protein, 281–282
- milk and milk products
  - consumption, 280
  - peak bone mass development, 280
  - postmenopausal bone loss, 280–281
  - risk of fracture, 281
- specified, 279
- UK plate model, 278–279

## Fracture

- BMD, 250, 297–298
- calcium
  - deficiency, 233–234
  - supplementation, 238
  - vitamin D, 222–223
- chronic low-grade systemic inflammation, 663–664
- dietary patterns, 123–129
- food fortification, 238–239
- hip, 416, 417
- human immunodeficiency virus
  - adults epidemiology, 647–648
  - children and adolescents epidemiology, 649
- low body weight, 564–565
- milk and milk products, 281
- protein deficiency, 232–233
- racial differences, 261–262
- risk
  - in alcohol consumption, 499–501
  - assessment, 88
  - in smoking, 494–496
- vitamin D, 223–224
  - deficiency, 234–235
  - supplementation, 237–238

## Fragility fractures, 232, 554

## Fruit and vegetables

- acid–base imbalance, 282–283
- population-based and intervention studies, 284
- potential renal acid load, 283–284

## G

## Gene–diet interactions

- areal bone mineral density, 22
- bone mineral content, 22
- candidate gene association studies, 22–23
- genome-wide association studies, 23–24
- human
  - calcium and vitamin D intake, 25–29
  - folate, 30
  - lipids, 30–31
  - methylenetetrahydrofolate reductase, 30

## PPAR gamma, 30–31

## VDR gene polymorphisms, 25–26

## Genome-wide association studies (GWAS), 23–24

## Ghrelin, 47

## Gingivitis, 134

glaOC. *See* Carboxylated form of osteocalcin (cOC)gluOC. *See* Undercarboxylated osteocalcin (ucOC)

## Gluten-free diet, 635, 639

## Gonadotropin-releasing hormone (GnRH), 603

## Growth hormone (GH) resistance, 606–607

## Growth-regulating hormones, 46–47

## H

## Heterogeneous nuclear ribonucleoproteins (hnRNPs), 462

## Hip fracture

## alcohol consumption, 499–500

## protein intake

## aBMD/BMC, 312

## cross-cultural comparison, 308–309

## prospective observational studies, 310–312

## protein repletion impact, 312–313

## smoking, 494–496

## Homocysteine, nutraceuticals, 588

## Hormone replacement therapy (HRT), 29, 530

## Hormone therapy (HT), 682

## Hot and cold beverages, 284–285

## 24-Hour Recall (24HR), 104–105

## Human immunodeficiency virus (HIV)

## adults epidemiology

## cross-sectional studies, 646–647

## fractures, 647–648

## longitudinal studies, 647

## antiretroviral therapy, 646

## calcium role, 652

## children and adolescents epidemiology

## cross-sectional studies, 648

## fractures, 649

## longitudinal studies, 648–649

## low BMD risk factors, 649

## vitamin D

## antiretrovirals, 650–651

## deficiency, 650

## screening and treatment, 651

## supplementation, 651

## zinc and vitamin A, 652

## Hydrogen ion buffering, 338–339

## 25-Hydroxyvitamin D, 265–266

## Hypercalciuria, 13

## Hyperparathyroidism, 636

## Hypervitaminosis, 410–411

## Hypogonadism, bone density

## amenorrhea, 603

## estrogen deficiency, 603–604

## GnRH, 603

## lack of improvement, 604

## testosterone, 605–606

## Hypophosphatemia, 387

**I**

- IDBPs. *See* Intracellular vitamin D-binding proteins (IDBPs)
- IGF-1, 74
- IGF-2, 46
- IL-6 gene, 29
- Immunosenscence, 660
- Inflammaging. *See* Chronic low-grade systemic inflammation
- Intestinal biopsy, 638
- Intracellular vitamin D-binding proteins (IDBPs)
  - heat-shockprotein-70, 465
  - 25-hydroxylated vitamin D metabolites, 464
  - intracellular trafficking, 466, 467
  - stable overexpression, consequences of, 465, 466
- In vivo acute metabolic acidosis, 336–337
- Iron, 693–694
- Isoflavones, 586
- Isotretinoin, 417, 418

**K**

- Kuopio OSTPRE Fracture Prevention Study, 328

**L**

- Lactation
  - bone mineral changes, 166–167
  - calcium and bone metabolism, 162, 165–166
  - osteoporosis incidence and fractures, 169, 171
- Leptin, 47
- Lipids, 30–31
  - adipose tissue, 322–324
  - BMD, 327
  - bone biomarkers, 329
  - circulatory, 324–325
  - fish, 328
  - low-carbohydrate–high-fat diet, 327
  - omega-3 fatty acid, 327
  - osteoporosis, 329
  - peroxisome proliferator-activated receptor-gamma, 325–326
  - postmenopausal women, 328
- Low body weight
  - bone mineral density, 564
  - bone turnover, 564
  - fracture risk, 564–565
- Low bone mass, 12
- Low insulin-like growth factor-I (IGF-I), 606–607

**M**

- Macrominerals, 395
- Macronutrients, 572
- Magnesium, 50
  - chronic low-grade systemic inflammation, 672–673
  - cystic fibrosis, 626
  - dietary sources, 145–146
  - nutraceuticals, 587–588

- parathyroid hormone values, 390
- RDA for, 389
- tolerance test, 390
- Malabsorption, 636
- Malnutrition, 239
- Maternal diet
  - calcium intake, 171–172
  - vitamin D intake
    - child outcomes, 176–177
    - fetal and neonatal outcomes, 173–175
    - infant outcomes, 175–176
    - potential risks, 177
- Maternal nutrition, 154, 187
- Matrix Gla Protein RNA expression, 343–344
- Maximal calcium retention curve, 363
- Meat/animal protein, 281–282
- Melanocortin 1 receptor (MC1R), 10
- Menaquinone-4 (MK-4), 472–474, 478, 479
- Menaquinone-7 (MK-7), 477, 479, 483
- Menkes' kinky hair syndrome, 396
- Metabolic acidosis, 336–337, 351
- Metabolic balance studies
  - application of, 362–363
  - balance run-in period, 364–365
  - dietary composites, 363, 364
  - free-living subjects vs. metabolic ward, 366–367
  - monitoring compliance, 365–366
  - polyethylene glycol, 364
  - prepared commercial foods, 363
  - whole-body wash-down procedure, 364
- Metabolic bone disease
  - cystic fibrosis, 618–619
  - parenteral nutrition, 153–154
- Metabolic syndrome, 136
- Methylenetetrahydrofolate reductase (MTHFR), 30
- Milk and milk products
  - chronic low-grade systemic inflammation, 666–667
  - consumption, 280
  - peak bone mass development, 280
  - postmenopausal bone loss, 280–281
  - risk of fracture, 281
- Musculoskeletal health, vitamin D deficiency on
  - bone histology, 436
  - osteomalacia, 435–437
  - rickets, 434, 435

**N**

- National Health and Nutrition Examination Survey (NHANES), 104, 135, 144
- National Osteoporosis Risk Assessment(NORA), 261
- Natto, 473
- Necrotizing enterocolitis, 397
- Neonatal bone, 172
- Net endogenous acid production (NEAP), 384
- Nonathletic children and adolescents, 510
- Non-collagenous proteins, 73
- Non-Markovian model, for calcium kinetics, 370

## Nutraceuticals

- bicarbonates, 587
- B vitamins and homocysteine, 588–589
- calcium and vitamin D, 590
- definition, 586
- dehydroepiandrosterone, 586
- DSHEA, 586
- minerals, 587–588
- phytoestrogens, 586–587
- vitamins and antioxidants, 589–590

## Nutrition

- adulthood and bone maintenance, 554
- bone health and food sources, 112
- bone studies
  - cross-sectional studies, 110–111
  - prospective studies, 111
  - systematic reviews and meta-analyses, 111–112
- calcium, 550–551
- cystic fibrosis, 626–627
- dietary intake assessment
  - food frequency questionnaire, 106
  - 24-Hour Recall, 104–105
- early life, childhood, and adolescence bone accrual, 553–554
- energy, 552–553
- fragility, 554
- life span, 553
- micronutrients
  - calcium intake assessment, 106–107
  - phosphorus intake assessment, 107–108
  - vitamin D intake assessment, 108–109
- osteoporosis prevention and management, 554–555
- periodontal diseases
  - alcohol, 139
  - alveolar bone loss, 134
  - cemento-enamel junction, 134
  - clinical measures, 139–140
  - diets, 135
  - gingivitis, 134
  - middle-aged and elderly persons, 135
  - obesity and metabolic syndrome, 136
  - oral bone loss, 136–138
  - plaque bacteria, 135
  - tooth loss and edentulism, 135
  - whole grains and dietary fiber, 136
- preterm infants (*see* Preterm infants)
- protein, 552
- serum 25-hydroxyvitamin D deficiency, 114
- vitamin D, 551–552

## Nutrition Care Process, 149

**O**

## Obesity

- body mass index, 562
- and bone, 562–564
- bone health, 149
- metabolic syndrome, 136

## Omega-3 fatty acids, 147

- chronic low-grade systemic inflammation, 673
- nutraceuticals, 589

space flight, 694–696

Omnivores, 295–298

Oral contraceptive use, 529

Oral nutritional supplements

- aged-care, 236
- falls and fractures, 236–237

Osteoblasts

- body composition, 565
- collagen synthesis, 341–342
- osteocytes, 43–44

Osteocalcin (OC), 473–474

Osteoclast, 42–43, 58–59

Osteocytes, 43–44

Osteoimmunology, 660

Osteomalacia, 435, 436

Osteopenia, CF patients

- causes, 619
- definition, 618

Osteopontin gene expression, 343–344

Osteoporosis, 12, 66

- anti-estrogenic smoking effect, 491
- bisphosphonates and denosumab, 683–684
- bone mass *vs.* age, 544–545

CF patients

- causes, 619
- definition, 618

characteristics, 544

chronic low-grade systemic inflammation

- dietary and supplemental calcium, 665–666
- dietary protein, 670–671
- effects, 663
- magnesium, 672–673
- milk and dairy foods, 666–667
- omega-3 fatty acids, 673
- soy protein and milk peptides, 671
- vitamin D (*see* Vitamin D)
- vitamin K, 671–672

combined treatment, 685

dietary link, 282–283

DXA, 86–87

estrogen and raloxifene, 682

and exercise, 525–529

exercise risks in, 534

lactation, 169, 171

nutrients *vs.* treatments, 682

peak bone mass, 544

prevention and management, 554–555

risk factor, 544

teriparatide, 684

US blacks, 250

Osteoprotegerin (OPG), 40

Overnutrition, 74–75

Oxalates, 294

**P**

Parathyroid hormone (PTH), 218, 666

25(OH)D, 251

1,25-dihydroxyvitamin D, 251, 252

skeletal resistance, 251–252

Parenteral nutrition, 153–154

- Peak bone mass
  - milk studies, 280
  - osteoporosis, 544
  - physical activity recommendations, 511–512
  - skeletal development, 200–202
  - smoking, 491
- Peptide YY (PYY), 607
- Periodontal diseases
  - alcohol, 139
  - alveolar bone loss, 134
  - cemento-enamel junction, 134
  - clinical measures, 139–140
  - diets, 135
  - gingivitis, 134
  - middle-aged and elderly persons, 135
  - obesity and metabolic syndrome, 136
  - oral bone loss, 136–138
  - plaque bacteria, 135
  - tooth loss and edentulism, 135
  - vitamin D, 139
  - whole grains and dietary fiber, 136
- Peripheral dual X-ray absorptiometry (pDXA), 84
- Peripheral quantitative computed tomography (pQCT), 84
- Peroxisome proliferator-activated receptor-gamma (PPAR- $\gamma$ ), 325–326
- Phosphorus
  - Ca:P molar ratio, 385, 389
  - cystic fibrosis, 626
  - dietary sources, 145–146
  - growth hormone, 385
  - hypophosphatemia, 387
  - intakes, 107–108, 113
  - nutraceuticals, 588
  - RDA, 387
  - regulation, 49–50
  - steady-state bone gain, 388
  - tricalcium phosphate, 386
  - Venn diagram, 387
- Phylloquinone, 472, 473, 477–479, 483
- Physical activity, 506
  - bone health
    - bone mineral density, 507–508
    - childhood and adolescence, 508–512
    - elderly, 548–549
    - midlife, 548
    - in older men, 520–525
    - in premenopausal women, 512–520
  - childhood and adolescence bone accrual, 546–547
  - exercise patterns, 507
  - exercise prescription, 546
  - mechanical loading, 545
  - nutrition and hormones, 555
  - voluntary weight reduction, 572–573
- Physically active lifestyles
  - historic times, 14–15
  - prehistoric times, 14
- Phytates, 294
- Phytoestrogens, 586–587
- Polyunsaturated fatty acids (PUFA), 147, 322
- Postmenopausal black women, 253
- Postmenopausal bone loss, 280–281
- Potassium
  - BMD, 384
  - effects, 383, 384
  - NEAP, 384
  - space flight, 696–697
  - transport mechanism, 383
  - vegetarian diets, 384
- Potential renal acid load (PRAL), 283–284
- PPAR gamma, 30–31
- Pregnancy
  - bone metabolism, 162–164
  - bone mineral changes, 164–165
  - calcium intake
    - fetal growth, 171
    - neonatal bone, 172
  - vitamin D intake
    - child outcomes, 176–177
    - fetal and neonatal outcomes, 173–175
    - infant outcomes, 175–176
    - potential risks, 177
- Preterm infants
  - boron role, 400–401
  - copper deficiency
    - animal studies, 397
    - human studies, 397–398
    - Menkes' kinky hair syndrome, 396
    - necrotizing enterocolitis, 397
    - radiological features, 397
  - fluoride intake, 403
  - silicon, 403
  - strontium, 401–402
  - zinc
    - animal studies, 399
    - clinical features, 399
    - human studies, 399, 400
    - osteoporosis, 399
- Progestins. *See* Estrogens
- Prostaglandins, 49, 345
- Protein, 293, 552
  - adult women, 308–310
  - bone acquisition, 303–305
  - bone matrix constituent, 301–302
  - calcium–phosphate economy, 302–303
  - deficiency, 232–233
  - elderly, 308–310
  - energy deficit, 307–308
  - hip fracture
    - aBMD/BMC, 312
    - cross-cultural comparison, 308–309
    - prospective observational studies, 310–312
    - protein repletion impact, 312–313
  - malnutrition, 212, 306–307
  - physical activity, 305–306
  - protein malnutrition, 306–307
  - racial differences, 266–267
  - repletion, 312–313

**Q**

- Quantitative clinical nutrition
  - calcium isotopic tracers, 367–368
  - kinetic studies
    - calcium metabolism, 368
    - mathematical modeling, 369–370
    - stable isotopes, 369
  - metabolic balance studies
    - application of, 362–363
    - compliance monitoring, 365–366
    - dermal calcium losses, 364
    - diets, 363
    - fecal calcium, 364–365
    - free-living subjects vs. metabolic ward, 366–367
    - menstrual calcium losses, 364
  - tracer studies, 367
- Quantitative computed tomography (QCT), 83–84, 600, 609
- Quantitative ultrasound (QUS), 84

**R**

- Rachitic bone lesion, 458
- Raloxifene, 682
- Recommended Dietary Allowance (RDA), 144
- Redclover, 587
- Retinol, 410, 413, 416, 417, 589–590
- Retinol Activity Equivalents (RAE), 412
- Rickets, 434
- Risedronate, 684

**S**

- Sarcopenia, 664–665
- Selective estrogen receptor modulators (SERMs), 47
- Serologic tests, 638
- Sex hormones, 47–48
- Silicon
  - effect, on bone and connective tissue, 497
  - nutraceuticals, 588
  - preterm infants, 403
- Skeletal development
  - calcium, 186–187
  - maternal nutrition, 187
  - minerals, 186
  - peak bone mass, 200–202
  - premature infants, 188
  - term-born infants, 188–189
- Skeletal fragility, 75
- Skeletal health
  - African Americans
    - BMD and fracture risk, 250
    - body size and composition, 251
    - calcium, 250, 252–254
    - parathyroid hormone, 251–252
    - vitamin D, 250, 252–254
  - alcohol consumption effects on, 496–497
  - bone density
    - caffeine consumption, 148
    - dietary patterns, 148
    - omega-3 fatty acids, 147

## bone mass

- fruits and vegetables, 146–147
  - protein, 147
  - calcium, 144
  - DGAC 2010, 154–155
  - diagnosis, 150–151
  - exercise, 149
  - fetal bone development, 154
  - fluoride, 145–146
  - intervention, 151–152
  - magnesium, 145–146
  - maternal nutrition, 154
  - metabolic bone disease, 153–154
  - monitoring and evaluation, 152–153
  - nutrition counseling, 149–150
  - obesity, 149
  - osteoporosis, 143
  - parenteral nutrition, 153–154
  - phosphorus, 145–146
  - populations, 148
  - racial/ethnic groups
    - areal bone mineral density, 260–261
    - BMI, 267
    - bone acquisition and loss, 263
    - bone size and microarchitecture, 262–263
    - calcium, 264–265
    - environmental factors, 264
    - fracture risk, 261–262
    - 25-hydroxyvitamin D, 265–266
    - protein, 266–267
    - PTH, 266
    - soy, 267
  - smoking effects, 490
  - soy, 149
  - USDA MyPlate, 156
  - vitamin C, 145
  - vitamin D, 144–145
- Skeletal modeling and bone consolidation
- adolescence
    - body weight, 209, 211
    - bone fragility fracture, 210
    - bone mass accumulation, 210, 212
    - calcium absorption, 206–207
    - calcium balances, 205
    - calcium deficiency, 210
    - estrogen, 204
    - fecal calcium, 212–213
    - insulin-like growth factor-I, 203
    - metacarpal cortical bone mass vs. bone volume, 206–207
    - nutrient interactions, 213–214
    - percent cortical area, 204–205
    - phosphorus balance, 211
    - protein–calorie malnutrition, 212
    - pubertal developmental stage, 203
    - relative total body calcium content, 209–210
    - serum calcitriol level, 206, 208
    - serum IGF-I, 212–213
    - total body calcium, 205–206, 209, 211

- urinary calcium vs. calcium intake, 208–209
- urinary calcium vs. urinary sodium, 208–209
- whole body calcium, 203–204
- childhood, 202–203, 213–214
- forearm bone mineral areal density, 199–200
- peak bone mass, 200–202
- total body nitrogen and minerals, 200–201
- Skeletal robusticity, 11
- Skylab studies, 689
- Smoking, 489
  - anti-estrogenic effect of, 491
  - bone mineral density
    - bone loss in women and men, 492–493
    - in mid-and late life, 492–494
    - peak bone mass, attainment of, 491
    - skeletal change over lifespan, 491
  - effects on skeletal health, 490
  - fracture risks, 494–496
  - pathophysiologic mechanisms, 490
- Sodium
  - space flight, 697
  - Western diet, 380
- Southampton Women's Study (SWS), 173
- Soy isoflavones, 267
- Soy products, 149
- Soy protein and milk peptides, 671
- Space flight
  - analog studies, 690
  - bone and calcium loss, 688–689
  - bone metabolism, 689–690
  - effects, 698
  - exercise, 690–692
  - iron, 693–694
  - omega-3 fatty acids, 694–696
  - potassium, 696–697
  - sodium, 697
  - vitamin D, 692–693
  - vitamin K, 697–698
- Steroid and xenobiotic nuclear receptor (SXR), 474
- Steroid hormone resistance, 460–462
- Strontium, 50
  - nutraceuticals, 588
  - preterm infants, 401–402
- Sunshine vitamin. *See* Vitamin D
- Systemic hormones, 45–46

## T

- Teriparatide, 612, 684
- Testosterone, 605–606
- Thyroid hormone, 46
- Trabecular microarchitecture, 70–72
- Trifolium pratense*. *See* Redclover
- Turner syndrome, 636

## U

- UK plate model, 278–279
- Undercarboxylated osteocalcin (ucOC), 474, 477–478
- Undernutrition, 74–75

## V

- VDRE-BP. *See* Vitamin D response element-binding protein (VDRE-BP)
- VDR gene polymorphisms, 25–26
- Vegetarian diets, 292
- Vegetarianism, 283
  - bone mineral density
    - bone mineral content, 295–296
    - calcium, 292–293
    - flavonoids, 294
    - fracture risk, 297–298
    - lumbar spine and femoral neck, 296
    - phytates/oxalates, 294
    - postmenopausal lacto-ovo vegetarians, 295
    - protein and acid/alkali balance, 293
    - vitamin B<sub>12</sub>, 294
    - vitamin D, 293
  - lifestyle factors, 294–295
  - vegetarian diets, 292
- Venn diagram, osteoporosis patients, 387
- Vitamin A, 409. *See also* Retinol
  - chronic toxicity of, 412
  - deficiency, 411
    - cancer risk, 410
    - characterization, 410
  - fish oil, 413
  - human immunodeficiency virus, 652
  - hypervitaminosis, 410–411
  - intake on bone health, 413–415
    - cross-sectional studies, 416
    - follow-up studies, 416–417
    - synthetic retinoids, 417–418
  - plasma level measurement, 413
  - recommended intake, 412
  - sources of, 410
  - supplements, 412
  - in vivo studies, 411
- Vitamin B<sub>12</sub>, 294
- Vitamin C. *See* Ascorbic acid
- Vitamin D, 10, 139
  - adequate vs. healthy intake, 443–444
  - African Americans
    - calcium intake, 250
    - observational studies, 252
    - postmenopausal black women, 253
    - Women's Health Initiative, 253–254
  - BMD, 293
  - body composition, 567
  - bone calcium mobilization, 425, 427
  - bone mineralization, 427
  - and cancer, 449
  - celiac disease, 636, 639
  - chronic low-grade systemic inflammation, 667
  - clinical recommendations, 226
  - cutaneous production of, 431–434
  - cystic fibrosis
    - absorption, 623
    - and bone, 624
    - health outcomes, 624
    - 25-hydroxyvitamin D, 622
    - metabolism, 622

Vitamin D (*cont.*)

- deficiency, 74
  - causes of, 439–442
  - definition, 424
  - diagnosis of, 441–442
  - fracture risk, 234–235
  - on musculoskeletal health, 434–437
  - nonskeletal consequences, 447–451
  - nonskeletal consequences of, 447–451
  - prevalence of, 437–438
  - treatment for, 444–447
- dietary sources, 144–145, 427–428, 430
- evolution of, 424
- falls, 221–222
- fracture rates, 222–224
- gene interactions, 26, 29
- human immunodeficiency virus
  - antiretrovirals, 650–651
  - deficiency, 650
  - screening and treatment, 651
  - supplementation, 651
- insufficiency, 424
- intake, 108–109, 113, 225, 571
- interpreting serum 25(OH)D levels, 444
- intracellular vitamin D-binding proteins, 464–467
- maternal diet
  - child outcomes, 176–177
  - fetal and neonatal outcomes, 173–175
  - infant outcomes, 175–176
  - potential risks, 177
- muscle performance, 221–222
- in New World primates
  - biochemical phenotype, 460, 461
  - evolution and rachitic bone lesion, 458
  - response element-binding protein, 463–464
  - retinoid X receptor, 462, 463
  - skeletal disease, 459–460
  - steroid hormone resistance, 460–462
  - synthesis and metabolism, 459, 460
- nutrition and bone health, 551–552
- osteoporosis, 682
- pharmacotherapy, 224
- physiology, 218–219
- PTH and bone loss, 220–221
- safety, 226
- in small intestine, 425
- sources of, 424, 427, 429
- space flight, 692–693
- sunlight exposure, 429, 431
- supplementation, 237–238
- synthesis and metabolism of, 425–427
- VDR gene polymorphisms, 25–28

## Vitamin D receptor gene (VDR), 23

## Vitamin D response element-binding protein (VDRE-BP)

- electromobility shift assay, 463
- silenced transactivation, 463–464

## Vitamin K

- in age-related bone loss
  - intervention studies, 478–479, 483
  - observational studies, 474–478
  - randomized clinical trials, 478–482

- chronic low-grade systemic inflammation, 671–672
  - cystic fibrosis, 624–625
  - dietary recommendations of, 473
  - in skeletal tissue, 474
  - space flight, 697–698
  - structures of, 472, 473
  - SXR activation, 474
  - VKD protein, 473–474
- Vitamin K<sub>1</sub>. *See* Phylloquinone
- Vitamin K<sub>2</sub>, 472, 671

## W

## Weaning

- bone mineral changes
  - bone loss, 167
  - bone outcomes, 169
  - calcium supplementation effects, 168
  - maternal age, 168
  - size-adjusted bone mineral content, 169–170
  - calcium and bone metabolism, 163, 167

## Weight reduction

- bone mineral density change, 568
- DXA measurement error, 574
- fat mass vs. serum estrone, 569
- involuntary, 569–570
- voluntary
  - bariatric surgery, 573–574
  - calcium intake, 571
  - macronutrients, 572
  - physical activity, 572–573
  - rate of, 570–571
  - vitamin D intake, 571
  - weight regain, 574–575

## Whole-body bone mineral content (WBBMC), 193–194

## Whole body calcium, 203–204

## Whole bone strength

- bone geometry, 69–70
- collagen characteristics, 73
- determinants, 67
- hierarchical nature of factors, 68
- material vs. structural properties, 68–69
- matrix mineralization, 72–73
- microdamage, 73
- non-collagenous proteins, 73
- trabecular microarchitecture, 70–72

## Whole grains and dietary fiber, 136

## Women's Health Initiative (WHI), 58, 253–254

## Z

## Zinc

- deficiency, 625
- human immunodeficiency virus, 652
- preterm infants
  - animal studies, 399
  - clinical features, 399
  - human studies, 399, 400
  - osteoporosis, 399

## Zoledronic acid, 684